High-throughput sequencing allows researchers to measure the expression of thousands of genes simultaneously, but raw expression data does not inherently reveal clinical relevance. Knowing that a gene is overexpressed in a tumor tissue does not tell us whether it actively drives the disease or merely acts as a bystander. To determine if a molecular feature truly matters to patient care, researchers must connect static molecular profiles with longitudinal clinical outcomes.
This is the core objective of prognostic value assessment. By statistically modeling how molecular variations correlate with patient survival metrics—such as overall survival (OS), disease-free survival (DFS), or relapse-free survival (RFS)—investigators can identify reliable biomarkers, stratify patient risk, and prioritize therapeutic targets.
Visualizing Survival Trajectories with Kaplan-Meier Estimators
The foundational tool for building intuition about a biomarker's clinical impact is the Kaplan-Meier (KM) survival curve. A KM curve plots the probability of an event (such as death or disease recurrence) over time.
To evaluate a gene's prognostic value, researchers typically stratify a patient population into distinct cohorts based on molecular abundance—most commonly splitting patients into "high expression" and "low expression" groups around a median or optimal threshold.
Patient Cohort ──► Stratification ──► Kaplan-Meier Plot ──► Log-Rank Test
├── High Exp (Visualizes (Evaluates
└── Low Exp Survival over Statistical
Time) Significance)
This stratification reveals the temporal trajectory of the disease. For instance, Yu Liu et al. used KM plots in Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis to demonstrate that elevated expression of the kinase PKMYT1 correlates with a steep decline in relapse-free survival among breast cancer patients. Similarly, Penglei Ge et al. applied KM analysis in Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma to show how immune microenvironment scores differentiate recurrence-free survival outcomes in liver cancer.
To confirm that the visual separation between two survival curves is meaningful rather than a product of random noise, researchers apply the log-rank test. The log-rank test compares the observed number of events in each group against the expected number of events under the null hypothesis (that the survival histories of both groups are identical). As shown by Zheng Feng et al. in Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC), this statistical framework provides a rigorous $p$-value to validate whether the presence of specific molecular markers serves as a dependable prognostic indicator.
Quantifying Risk via Cox Proportional Hazards Regression
While KM curves offer an intuitive visualization, they possess a major limitation: they require continuous expression data to be forced into binary categories (high vs. low), which discards valuable granular information. Furthermore, KM curves cannot easily account for multiple variables at once. A gene might appear to predict poor survival simply because it is more active in older patients or advanced-stage tumors.
To isolate the true independent effect of a molecular marker, researchers turn to the Cox proportional hazards regression model. Instead of plotting a curve, the Cox model estimates the hazard function—the instantaneous rate of an event occurring at a specific time point, given that the patient has survived up to that moment.
The model assumes that a patient's risk is a multiplicative combination of a baseline hazard and an exponential function of their clinical and molecular covariates:
$$\lambda(t | X) = \lambda_0(t) \exp(\beta_1 X_1 + \beta_2 X_2 + \dots)$$
This mathematical formulation yields a Hazard Ratio (HR) for each variable:
- $\text{HR} > 1$: Higher expression or presence of the marker increases the risk of the event (associated with poorer prognosis).
- $\text{HR} < 1$: The marker reduces risk, indicating a protective effect or better prognosis.
By including clinical covariates like age, sex, and tumor stage alongside gene expression levels, the Cox model determines if a biomarker provides independent prognostic value.
In IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma, Zhihui Liu et al. combined Cox regression with KM curves to evaluate a multi-gene risk score ("IGFBPScore") in glioma. Similarly, Ke Xu et al. deployed Cox proportional hazards models in SLC22A8: An indicator for tumor immune microenvironment and prognosis of ccRCC from a comprehensive analysis of bioinformatics to calculate the precise risk metrics associated with SLC22A8 expression levels in renal cell carcinoma.
Scaling to Public Repositories and Pan-Cancer Frameworks
The widespread adoption of survival-linked expression modeling is accelerated by large-scale, publicly accessible clinical-genomic repositories. Databases like The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) portal pair deep molecular sequencing with years of longitudinal clinical tracking for thousands of patients.
Web-based analytical suites—such as the Kaplan-Meier Plotter, GEPIA, and PrognoScan—have democratized these statistical workflows, allowing researchers to instantly validate candidate genes across expansive cohorts.
Candidate Gene ──► Public Databases (TCGA / GTEx) ──► Analytical Tools (GEPIA / PrognoScan) ──► Population-Level Validation
This public infrastructure allows investigators to scale their analyses from single-cancer studies to comprehensive "pan-cancer" evaluations. For example, Qiang Peng et al. utilized TCGA and GTEx datasets in GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer to confirm the prognostic value of GLIS1. Guoliang Cui et al. deployed PrognoScan and Kaplan-Meier Plotter in CFP is a prognostic biomarker and correlated with immune infiltrates in Gastric Cancer and Lung Cancer to cross-validate Complement Factor Properdin across multiple distinct organ sites.
Furthermore, Ke Wang et al. demonstrated the power of pan-cancer modeling in Prognosis and immunological characteristics of HDAC family in pan-cancer through integrative multi-omic analysis, mapping how the entire Histone Deacetylase family influences survival across 33 different cancer types simultaneously.
Beyond identifying static biomarkers, these survival models can adapt to complex clinical dynamics, such as therapeutic interventions. By isolating patient cohorts exposed to specific treatments within public datasets, computational pipelines can uncover gene-drug interactions. As demonstrated by Peng Qiu in Identification of gene-drug interactions that impact patient survival in TCGA, tracking how genetic variations like copy number alterations shift survival curves exclusively under specific drug exposures provides a direct, data-driven pathway toward personalized medicine.
Key Foundational Work
High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients (2011) — contributed 1 concept elements to this direction.
Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients (2006) — contributed 1 concept elements to this direction.